Get the Stockscreener App
1.69
4.52%
-0.08
After Hours:
1.70
0.01
+0.59%
Caribou Biosciences Inc stock is traded at $1.69, with a volume of 482.10K.
It is down -4.52% in the last 24 hours and down -10.58% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$1.77
Open:
$1.76
24h Volume:
482.10K
Relative Volume:
0.22
Market Cap:
$157.96M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.1575
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
+6.29%
1M Performance:
-10.58%
6M Performance:
+5.62%
1Y Performance:
-1.74%
1-Day Range:
$1.68
$1.765
1-Week Range:
$1.54
$1.80
52-Week Range:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.69 | 165.44M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
How sustainable is Caribou Biosciences Inc. stock dividend payoutShort Interest Overview & Superior Growth Investment - bollywoodhelpline.com
How Caribou Biosciences Inc. stock trades before earningsPortfolio Return Report & AI Based Trade Execution Alerts - ulpravda.ru
Can Caribou Biosciences Inc. stock sustain revenue growthM&A Rumor & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Income Plays: How analysts rate Caribou Biosciences Inc. stock todayMarket Risk Summary & High Conviction Buy Zone Picks - ulpravda.ru
What is the fair value of Caribou Biosciences Inc. stock nowGeopolitical Risk Analysis & Missed Nvidia? Don’t Miss This One - ulpravda.ru
Can Caribou Biosciences Inc. stock continue upward trendMean Reversion Trades & Big Gains Low Budget - ulpravda.ru
Aug Intraday: Can Caribou Biosciences Inc stock sustain revenue growthMarket Weekly Review & Daily Volume Surge Trade Alerts - moha.gov.vn
Caribou Biosciences (CRBU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Caribou Biosciences Inc stock remain a Wall Street favoriteGold Moves & Low Risk Entry Point Guides - moha.gov.vn
What valuation multiples suggest for Caribou Biosciences Inc. stockGap Fill Strategies & Affordable Growth Investments - bollywoodhelpline.com
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Caribou Biosciences (NASDAQ:CRBU) Trading Up 2.4%Should You Buy? - MarketBeat
Why Caribou Biosciences Inc. stock is popular among millennialsJuly 2025 News Drivers & Weekly Momentum Picks - Улправда
Would You Still Hold Caribou Biosciences Stock If It Fell Another 30%? - Trefis
Will Caribou Biosciences Inc. stock benefit from automationWeekly Market Outlook & Low Risk High Reward Trade Ideas - Bölüm Sonu Canavarı
How analysts rate Caribou Biosciences Inc. stock today2025 Short Interest & Accurate Entry and Exit Point Alerts - DonanımHaber
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Published on: 2025-12-19 16:09:33 - Улправда
Can Caribou Biosciences Inc. stock sustain institutional interestJuly 2025 Setups & Smart Swing Trading Alerts - DonanımHaber
How risky is Caribou Biosciences Inc. stock nowQuarterly Market Review & Free High Accuracy Swing Entry Alerts - DonanımHaber
Wall Street Recap: Why hedge funds are buying Caribou Biosciences Inc. stock2025 Historical Comparison & Consistent Profit Trading Strategies - Улправда
Targets Report: How sustainable is Caribou Biosciences Inc. stock dividend payoutWeekly Trade Report & Real-Time Volume Trigger Notifications - Улправда
Will Caribou Biosciences Inc. stock remain a Wall Street favoriteM&A Rumor & Reliable Entry Point Alerts - Улправда
Published on: 2025-12-19 08:19:09 - Улправда
Published on: 2025-12-19 00:46:22 - Улправда
What analyst consensus says on Caribou Biosciences Inc. stockJuly 2025 Action & High Accuracy Buy Signal Tips - Улправда
Market Overview: Why Caribou Biosciences Inc. stock is a value investor pickJuly 2025 Technicals & Free Weekly Chart Analysis and Trade Guides - Улправда
Chart Watch: How risky is Caribou Biosciences Inc stock nowWeekly Trade Review & AI Enhanced Trading Alerts - moha.gov.vn
Caribou Biosciences Earnings Notes - Trefis
Published on: 2025-12-14 05:29:10 - earlytimes.in
Bank of America Securities Sticks to Their Buy Rating for Caribou Biosciences (CRBU) - The Globe and Mail
Will Caribou Biosciences Inc. stock reach Wall Street targets2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - Newser
Caribou Biosciences Target of Unusually Large Options Trading (NASDAQ:CRBU) - MarketBeat
Caribou Biosciences to Host Expert Panel on Access Expansion for vispa-cel CAR-T Therapy at ASH Annual Meeting - Quiver Quantitative
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 - 富途牛牛
MACD Signal: Will ABEV stock outperform value stocksJuly 2025 Earnings & Accurate Intraday Trading Signals - BỘ NỘI VỤ
Earnings Risk: What analyst consensus says on Caribou Biosciences Inc stockJuly 2025 Pullbacks & Free Daily Entry Point Trade Alerts - BỘ NỘI VỤ
Caribou Biosciences CEO to address Evercore Healthcare Conference - Traders Union
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Caribou Biosciences, Inc. $CRBU Shares Bought by Envestnet Asset Management Inc. - MarketBeat
Caribou Biosciences signals access challenge in CAR-T cell therapy - Traders Union
Analyzing Caribou Biosciences Inc. with multi timeframe chartsJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
Is Caribou Biosciences Inc. stock positioned well for digital economyJuly 2025 Intraday Action & Long-Term Safe Investment Plans - newser.com
Caribou Biosciences Inc. (CRBU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is it time to cut losses on Caribou Biosciences Inc.Rate Hike & Verified Momentum Stock Watchlist - newser.com
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):